Zydus Lifesciences has received the EIR report from the United States Food and Drug Administration (USFDA) for the inspection conducted at its API manufacturing facility located at Ambernath, Maharashtra. This facility underwent an inspection from February 10 to February 14, 2025, and had ended with NIL observations. The EIR report has classified it as No Action Indicated (NAI).
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
